mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features
Authors
Keywords
Pituitary adenoma, mTOR, Erk, Akt, Immunohistochemistry
Journal
ENDOCRINE PATHOLOGY
Volume 24, Issue 1, Pages 11-19
Publisher
Springer Nature
Online
2013-01-07
DOI
10.1007/s12022-012-9230-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nelfinavir induces radiation sensitization in pituitary adenoma cells
- (2011) Jing Zeng et al. CANCER BIOLOGY & THERAPY
- Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood
- (2011) Maja-Theresa Dieterlen et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Glucocorticoid suppresses BDNF-stimulated MAPK/ERK pathway via inhibiting interaction of Shp2 with TrkB
- (2011) Emi Kumamaru et al. FEBS LETTERS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- New targeted therapies in pituitary carcinoma resistant to temozolomide
- (2011) Emmanuel Jouanneau et al. Pituitary
- The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells
- (2010) V. Cerovac et al. CANCER RESEARCH
- Immunohistochemical Expression of Pituitary Tumor Transforming Gene (PTTG) in Pituitary Adenomas: A Correlative Study of Tumor Subtypes
- (2010) Fateme Salehi et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- The pathophysiology of pituitary adenomas
- (2009) Dorota Dworakowska et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
- (2009) Michael W. Ronellenfitsch et al. BRAIN
- Key factors in mTOR regulation
- (2009) Xiaochun Bai et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma
- (2009) K. E. O'Reilly et al. CLINICAL CANCER RESEARCH
- Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
- (2009) Alexander Gorshtein et al. ENDOCRINE-RELATED CANCER
- Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
- (2009) D Dworakowska et al. ENDOCRINE-RELATED CANCER
- Predicting Recurrence of Nonfunctioning Pituitary Adenomas
- (2009) Tae-Woong Noh et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas
- (2009) Maria Chiara Zatelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- KI-67 IN PITUITARY NEOPLASMS
- (2009) Fateme Salehi et al. NEUROSURGERY
- The role of mTOR in the management of solid tumors: An overview
- (2008) Alex S. Strimpakos et al. CANCER TREATMENT REVIEWS
- Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy
- (2008) B. B. Friday et al. CLINICAL CANCER RESEARCH
- Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas
- (2008) Elias Drakos et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune–Albright syndrome, familial acromegaly and genetic defects in sporadic tumors
- (2008) Anelia Horvath et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now